Anavex Life Sciences Corp (STU:12X1)
€ 11.68 2.842 (32.16%) Market Cap: 985.54 Mil Enterprise Value: 858.70 Mil PE Ratio: 0 PB Ratio: 8.54 GF Score: 41/100

Q3 2024 Anavex Life Sciences Corp Earnings Call Transcript

Aug 06, 2024 / 12:30PM GMT
Release Date Price: €6.39 (+18.94%)
Clint Tomlinson
Anavex Life Sciences Corp - IR

Good morning, and welcome to the Anavex Life Sciences Fiscal 2024 Third Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. (Operator Instructions) With us today is Dr. Christopher Missling, President, and Chief Executive Officer; and Sandra Boenisch Principal Financial Officer. Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements.

These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company's filings with the SEC. This includes, without limitation, the company's Forms 10-K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements.

These factors may include, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot